¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º(AMR) Áø´Ü ½ÃÀå : ¾÷°è ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Antimicrobial Resistance Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°è Ç×»ýÁ¦ ³»¼º(AMR) Áø´Ü ½ÃÀå ±Ô¸ð´Â 2025³â 48¾ï 3,070¸¸ ´Þ·¯¿¡¼ 2025-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 6.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 76¾ï 2,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Ç×»ýÁ¦ ³»¼º(AMR) Áø´ÜÀº ¹Ì»ý¹° º´¿øÃ¼ÀÇ Ç×»ýÁ¦ ³»¼ºÀ» °¨ÁöÇÏ°í ´ëóÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. AMR Áø´Ü ½ÃÀåÀº º´¿ø, Áø´Ü¼¾ÅÍ, Ŭ¸®´Ð¿¡ ¼ºñ½º¸¦ Á¦°øÇϰí, ºÐÀÚÁø´Ü, ¹è¾ç¹ý, ½Å¼ÓÁø´Ü°Ë»ç µî ´Ù¾çÇÑ Áø´Ü ÅøÀ» Á¦°øÇϸç, º´¿ø, Áø´Ü¼¾ÅÍ, Ŭ¸®´Ð¿¡ ¼ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¾àÁ¦ ³»¼º °¨¿°Áõ Áõ°¡, AMR¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Ä¡·á ¼º°ú Çâ»óÀ» À§ÇÑ ¸ÂÃã ÀÇ·á¿¡ ´ëÇÑ ´ÏÁî Áõ°¡ÀÔ´Ï´Ù.
¼¼°è AMR Áø´Ü ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î ¾àÁ¦ ³»¼º °¨¿°ÁõÀÇ È®»ê°ú °°Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ³»¼º º´¿øÃ¼°¡ °è¼Ó ÃâÇöÇÔ¿¡ µû¶ó ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü´Â °¨¿°º´À» È¿°úÀûÀ¸·Î Ä¡·áÇÏ´Â µ¥ Å« ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, ÀÌ´Â Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Â÷¼¼´ë ¿°±â¼¿ ºÐ¼®, ´ÙÁß PCR °Ë»ç µî ÷´Ü Áø´Ü µµ±¸ÀÇ °³¹ßÀº ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, AMR ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎ ¹× ÀÇ·á±â°üÀÇ Áö¿ø Áõ°¡¿Í AMR Áø´Ü ¼Ö·ç¼ÇÀÇ ÀÓ»óÀû ÅëÇÕÀº ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×±ÕÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ¹× °¨¿° °ü¸® ´ëÃ¥ °³¼±¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó AMR Áø´ÜÀÇ Ã¤ÅÃÀÌ °¡¼Ó鵃 °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
AMR Áø´Ü ½ÃÀåÀº À¯¸ÁÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÁö¸¸, ƯÈ÷ ½ÅÈï±¹¿¡¼ ƯÁ¤ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ³ôÀº ºñ¿ë°ú »óȯ Á¦ÇѰú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Áø´Ü ±â¼úÀÇ ½ÂÀÎ ÀýÂ÷ ¹× ±¹Á¦ Ç¥ÁØ Áؼö¿Í °°Àº ±ÔÁ¦Àû Àå¾Ö¹°µµ ½ÃÀå ÁøÀÔÀ» Áö¿¬½ÃŰ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ È¯ÀÚ Áý´Ü¿¡¼ º´¿ø±ÕÀÇ ³»¼º ±ÕÁÖ¸¦ Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸ÀÇ °³¹ßÀº º¹ÀâÇϱ⠶§¹®¿¡ ±â¼úÀûÀÎ ¹®Á¦µµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼ AMR Áø´ÜÀÇ º¸±ÞÀ» °¡·Î¸·´Â À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
AMR Áø´Ü ½ÃÀåÀº ºÐÀÚÁø´ÜÇÐ, AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®ÀÇ ¹ßÀüÀ¸·Î Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Áø´Ü Ç÷§Æû¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» Á¢¸ñÇÏ¸é ³»¼º º´¿ø±ÕÀ» º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ¾î ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» ¿ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ¸ÂÃãÇü Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±âȸµµ Á¦°øµË´Ï´Ù. Áø´Ü ±â¾÷, ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü, Á¤ºÎ ±â°üÀÇ ÆÄÆ®³Ê½ÊÀº Á¢±Ù À庮À» ±Øº¹Çϰí Àü ¼¼°è ÀÇ·á ȯ°æ¿¡¼ AMR Áø´Ü µµ±¸ÀÇ °¡¿ë¼ºÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º(AMR) Áø´Ü ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç° À¯Çüº°/±â¼úº°/º´¿øÃ¼ À¯Çüº°/ÃÖÁ¾»ç¿ëÀÚº°/Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
°Å½Ã°æÁ¦ ¿äÀÎ
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Á¦4Àå ¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, 2025³â-2032³â
¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á : Á¦Ç° À¯Çüº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, Á¦Ç° À¯Çüº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Á¦Ç° À¯Çüº°, 2025³â-2032³â
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç° À¯Çüº°
¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á : ±â¼úº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, ±â¼úº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ±â¼úº°, 2025³â-2032³â
ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)
¹Ì»ý¹°ÇÐ ¹è¾ç
¸é¿ªÃøÁ¤
Â÷¼¼´ë ½ÃÄö½Ì(NGS)
Áú·®ºÐ¼®
POC(Point of Care)
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ±â¼úº°
¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á : º´¿øÃ¼ À¯Çüº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, º´¿øÃ¼ À¯Çüº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, º´¿øÃ¼ À¯Çüº°, 2025³â-2032³â
¸ÞƼ½Ç¸° ³»¼º Ȳ»ö Æ÷µµ±¸±Õ(MRSA)
¾àÁ¦ ³»¼º Æó·Å±¸±Õ(DRSP)
¾àÁ¦ ³»¼º įÇʷιÚÅÍ(DRC)
Ŭ·Î½ºÆ®¸®µð¿ò µðÇǽÇ(CD)
¾àÁ¦ ³»¼º ÀÓ±Õ(DRNG)
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : º´¿øÃ¼ À¯Çüº°
¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, ÃÖÁ¾»ç¿ëÀÚº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2025³â-2032³â
º´¿ø ¹× Áø·á¼Ò
Áø´Ü ½ÇÇè½Ç
¿¬±¸±â°ü
Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
Á¦5Àå ¼¼°èÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®, Áö¿ªº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025³â-2032³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦6Àå ºÏ¹ÌÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦7Àå À¯·´ÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç×»ýÁ¦ ³»¼º Áø´Ü ½ÃÀå Àü¸Á
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
½ÃÀå ±¸Á¶
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
bioMerieux
Roche Diagnostics
Cepheid
Hologic, Inc.
Thermo Fisher Scientific
Illumina, Inc.
Oxford Nanopore Technologies
Pacific Biosciences(PacBio)
Qiagen
Agilent Technologies
Randox Laboratories
Bruker Corporation
Becton, Dickinson and Company(BD)
±âŸ
Á¦13Àå ºÎ·Ï
LSH
Persistence Market Research has recently released a comprehensive report on the worldwide market for antimicrobial resistance (AMR) diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global AMR diagnostics market from 2025 to 2032.
Key Insights:
AMR Diagnostics Market Size (2025E): USD 4,830.7 Million
Projected Market Value (2032F): USD 7,620.1 Million
Global Market Growth Rate (CAGR 2025 to 2032): 6.7%
AMR Diagnostics Market - Report Scope:
Antimicrobial resistance (AMR) diagnostics play a crucial role in detecting and addressing antibiotic resistance in microbial pathogens. These diagnostics are vital for accurate identification and treatment of resistant infections, which is critical in preventing the misuse of antibiotics and promoting effective treatment regimens. The AMR diagnostics market serves hospitals, diagnostic centers, and clinics, offering a range of diagnostic tools including molecular diagnostics, culture-based methods, and rapid diagnostic tests. Market growth is driven by the increasing prevalence of drug-resistant infections, rising awareness of AMR, and the growing need for personalized medicine to improve treatment outcomes.
Market Growth Drivers:
The global AMR diagnostics market is driven by several key factors, including the escalating prevalence of antimicrobial-resistant infections worldwide. As resistant pathogens continue to emerge, healthcare providers face significant challenges in treating infections effectively, which propels the demand for accurate and rapid diagnostics. Additionally, the increasing investment in R&D and the development of advanced diagnostic tools, such as next-generation sequencing and multiplex PCR tests, is boosting market expansion. The rising government and healthcare agency support for AMR awareness programs and the integration of AMR diagnostic solutions into clinical practice further contribute to market growth. Furthermore, the growing emphasis on antimicrobial stewardship programs and improved infection control measures is expected to accelerate the adoption of AMR diagnostics.
Market Restraints:
Despite promising growth prospects, the AMR diagnostics market faces challenges related to high costs and limited reimbursement for certain diagnostic tests, particularly in emerging economies. Regulatory hurdles, such as lengthy approval processes for new diagnostic technologies and compliance with international standards, can also slow market entry. Moreover, the complexity of developing diagnostic tools that accurately identify resistant strains of pathogens across diverse patient populations presents technical challenges. These factors create barriers to the widespread adoption of AMR diagnostics, particularly in regions with limited healthcare infrastructure.
Market Opportunities:
The AMR diagnostics market presents significant growth opportunities driven by advancements in molecular diagnostics, AI-powered diagnostic tools, and real-time data analysis. The integration of artificial intelligence and machine learning into diagnostic platforms enables faster and more accurate detection of resistant pathogens, creating new avenues for market expansion. Additionally, the increasing focus on personalized medicine and precision healthcare provides opportunities for tailored diagnostic solutions to improve treatment outcomes. Partnerships between diagnostic companies, healthcare providers, and government agencies will help overcome barriers to access and expand the availability of AMR diagnostic tools across global healthcare settings.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the AMR diagnostics market globally?
Which diagnostic methods and technologies are most widely adopted across healthcare settings?
How are technological advancements reshaping the competitive landscape of the AMR diagnostics market?
Who are the key players contributing to the AMR diagnostics market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global AMR diagnostics market?
Competitive Intelligence and Business Strategy:
Leading players in the global AMR diagnostics market, including Roche Diagnostics, Abbott Laboratories, BioMerieux, and Cepheid, focus on innovation, product differentiation, and strategic partnerships to maintain their competitive edge. These companies invest in R&D to develop advanced diagnostic technologies such as next-generation sequencing, CRISPR-based diagnostics, and multiplex PCR tests. Collaborations with healthcare providers, academic institutions, and regulatory agencies are essential for accelerating the adoption of AMR diagnostics and ensuring compliance with evolving global standards. Additionally, increased focus on patient education and AMR awareness initiatives supports the market growth and enhances the effectiveness of diagnostic tools in combating antimicrobial resistance.
Key Companies Profiled:
Abbott Laboratories
Accelerated Diagnostics, USA
Alifax
Bio-Rad Laboratories
BioMerieux
Beckman Coulter
Becton, Dickinson and Company
F.Hoffmann-La Roche
Molsid
Thermo Fisher Scientific
Vela Diagnostics
Others
AMR Diagnostics Market Research Segmentation:
The AMR diagnostics market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various clinical needs and patient populations.
By Product Type
Instruments
Reagents & Consumables
By Technology
Polymerase Chain Reaction (PCR)
Microbiology Culture
Immunoassay
Next-generation sequencing (NGS)
Mass Spectrometry
Point-of-care
Others
By Pathogen Type
Methicillin-resistant Staphylococcus aureus (MRSA)
Drug-resistant Streptococcus pneumoniae (DRSP)
Drug-resistant Campylobacter (DRC)
Clostridium difficile (CD)
Drug-resistant Neisseria gonorrhoeae (DRNG)
Others
By End-user
Hospitals & Clinics
Diagnostics Laboratories
Research Institutes
Pharmaceutical & Biotechnology Companies
Others
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Global Antimicrobial Resistance Diagnostics Market Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Type Adoption Analysis
3.3. Technological Advancements
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Global Antimicrobial Resistance Diagnostics Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Antimicrobial Resistance Diagnostics Market Outlook: Product Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Product Type, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
4.3.3.1. Instruments
4.3.3.2. Reagents & Consumables
4.3.4. Market Attractiveness Analysis: Product Type
4.4. Global Antimicrobial Resistance Diagnostics Market Outlook: Technology
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By Technology, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
4.4.3.1. Polymerase Chain Reaction (PCR)
4.4.3.2. Microbiology Culture
4.4.3.3. Immunoassay
4.4.3.4. Next-Generation Sequencing (NGS)
4.4.3.5. Mass Spectrometry
4.4.3.6. Point-of-care
4.4.3.7. Others
4.4.4. Market Attractiveness Analysis: Technology
4.5. Global Antimicrobial Resistance Diagnostics Market Outlook: Pathogen Type
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Pathogen Type, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
4.5.3.1. Methicillin-resistant Staphylococcus aureus (MRSA)
4.5.3.2. Drug-resistant Streptococcus pneumoniae (DRSP)
4.5.3.3. Drug-resistant Campylobacter (DRC)
4.5.3.4. Clostridium difficile (CD)
4.5.3.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
4.5.3.6. Others
4.5.4. Market Attractiveness Analysis: Pathogen Type
4.6. Global Antimicrobial Resistance Diagnostics Market Outlook: End-user
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2019-2024
4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
4.6.3.1. Hospitals & Clinics
4.6.3.2. Diagnostics Laboratories
4.6.3.3. Research Institutes
4.6.3.4. Pharmaceutical & Biotechnology Companies
4.6.3.5. Others
4.6.4. Market Attractiveness Analysis: End-user
5. Global Antimicrobial Resistance Diagnostics Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Antimicrobial Resistance Diagnostics Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Product Type
6.2.3. By Technology
6.2.4. By Pathogen Type
6.2.5. By End-user
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
6.4.1. Instruments
6.4.2. Reagents & Consumables
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
6.5.1. Polymerase Chain Reaction (PCR)
6.5.2. Microbiology Culture
6.5.3. Immunoassay
6.5.4. Next-Generation Sequencing (NGS)
6.5.5. Mass Spectrometry
6.5.6. Point-of-care
6.5.7. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
6.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
6.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
6.6.3. Drug-resistant Campylobacter (DRC)
6.6.4. Clostridium difficile (CD)
6.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
6.6.6. Others
6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
6.7.1. Hospitals & Clinics
6.7.2. Diagnostics Laboratories
6.7.3. Research Institutes
6.7.4. Pharmaceutical & Biotechnology Companies
6.7.5. Others
6.8. Market Attractiveness Analysis
7. Europe Antimicrobial Resistance Diagnostics Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product Type
7.2.3. By Technology
7.2.4. By Pathogen Type
7.2.5. By End-user
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
7.4.1. Instruments
7.4.2. Reagents & Consumables
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
7.5.1. Polymerase Chain Reaction (PCR)
7.5.2. Microbiology Culture
7.5.3. Immunoassay
7.5.4. Next-Generation Sequencing (NGS)
7.5.5. Mass Spectrometry
7.5.6. Point-of-care
7.5.7. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
7.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
7.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
7.6.3. Drug-resistant Campylobacter (DRC)
7.6.4. Clostridium difficile (CD)
7.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
7.6.6. Others
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
7.7.1. Hospitals & Clinics
7.7.2. Diagnostics Laboratories
7.7.3. Research Institutes
7.7.4. Pharmaceutical & Biotechnology Companies
7.7.5. Others
7.8. Market Attractiveness Analysis
8. East Asia Antimicrobial Resistance Diagnostics Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product Type
8.2.3. By Technology
8.2.4. By Pathogen Type
8.2.5. By End-user
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
8.4.1. Instruments
8.4.2. Reagents & Consumables
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
8.5.1. Polymerase Chain Reaction (PCR)
8.5.2. Microbiology Culture
8.5.3. Immunoassay
8.5.4. Next-Generation Sequencing (NGS)
8.5.5. Mass Spectrometry
8.5.6. Point-of-care
8.5.7. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
8.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
8.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
8.6.3. Drug-resistant Campylobacter (DRC)
8.6.4. Clostridium difficile (CD)
8.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
8.6.6. Others
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
8.7.1. Hospitals & Clinics
8.7.2. Diagnostics Laboratories
8.7.3. Research Institutes
8.7.4. Pharmaceutical & Biotechnology Companies
8.7.5. Others
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Antimicrobial Resistance Diagnostics Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product Type
9.2.3. By Technology
9.2.4. By Pathogen Type
9.2.5. By End-user
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
9.4.1. Instruments
9.4.2. Reagents & Consumables
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
9.5.1. Polymerase Chain Reaction (PCR)
9.5.2. Microbiology Culture
9.5.3. Immunoassay
9.5.4. Next-Generation Sequencing (NGS)
9.5.5. Mass Spectrometry
9.5.6. Point-of-care
9.5.7. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
9.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
9.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
9.6.3. Drug-resistant Campylobacter (DRC)
9.6.4. Clostridium difficile (CD)
9.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
9.6.6. Others
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
9.7.1. Hospitals & Clinics
9.7.2. Diagnostics Laboratories
9.7.3. Research Institutes
9.7.4. Pharmaceutical & Biotechnology Companies
9.7.5. Others
9.8. Market Attractiveness Analysis
10. Latin America Antimicrobial Resistance Diagnostics Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product Type
10.2.3. By Technology
10.2.4. By Pathogen Type
10.2.5. By End-user
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
10.4.1. Instruments
10.4.2. Reagents & Consumables
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
10.5.1. Polymerase Chain Reaction (PCR)
10.5.2. Microbiology Culture
10.5.3. Immunoassay
10.5.4. Next-Generation Sequencing (NGS)
10.5.5. Mass Spectrometry
10.5.6. Point-of-care
10.5.7. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
10.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
10.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
10.6.3. Drug-resistant Campylobacter (DRC)
10.6.4. Clostridium difficile (CD)
10.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
10.6.6. Others
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
10.7.1. Hospitals & Clinics
10.7.2. Diagnostics Laboratories
10.7.3. Research Institutes
10.7.4. Pharmaceutical & Biotechnology Companies
10.7.5. Others
10.8. Market Attractiveness Analysis
11. Middle East & Africa Antimicrobial Resistance Diagnostics Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product Type
11.2.3. By Technology
11.2.4. By Pathogen Type
11.2.5. By End-user
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2025-2032
11.4.1. Instruments
11.4.2. Reagents & Consumables
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
11.5.1. Polymerase Chain Reaction (PCR)
11.5.2. Microbiology Culture
11.5.3. Immunoassay
11.5.4. Next-Generation Sequencing (NGS)
11.5.5. Mass Spectrometry
11.5.6. Point-of-care
11.5.7. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Pathogen Type, 2025-2032
11.6.1. Methicillin-resistant Staphylococcus aureus (MRSA)
11.6.2. Drug-resistant Streptococcus pneumoniae (DRSP)
11.6.3. Drug-resistant Campylobacter (DRC)
11.6.4. Clostridium difficile (CD)
11.6.5. Drug-resistant Neisseria gonorrhoeae (DRNG)
11.6.6. Others
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025-2032
11.7.1. Hospitals & Clinics
11.7.2. Diagnostics Laboratories
11.7.3. Research Institutes
11.7.4. Pharmaceutical & Biotechnology Companies
11.7.5. Others
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. bioMerieux
12.3.1.1. Overview
12.3.1.2. Segments and Product Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Roche Diagnostics
12.3.3. Cepheid
12.3.4. Hologic, Inc.
12.3.5. Thermo Fisher Scientific
12.3.6. Illumina, Inc.
12.3.7. Oxford Nanopore Technologies
12.3.8. Pacific Biosciences (PacBio)
12.3.9. Qiagen
12.3.10. Agilent Technologies
12.3.11. Randox Laboratories
12.3.12. Bruker Corporation
12.3.13. Becton, Dickinson and Company (BD)
12.3.14. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations